Select your language

 

Chairman’s message

Yoann PointreauDr Yoann PointreauOncology and Radiotherapy ILC Le Mans

Dear Colleagues, Dear Friends, Dear Everyone,

This brand-new issue of the journal revisits the main discussions from last December’s meetings in Charenton, once again chosen as the venue, as it was last year.
You were very many in attendance, and these days provided an opportunity to announce our record number of members.
These meetings allowed us to review completed clinical trials, some of which have now been published, reflecting GORTEC’s national and international standing.
We also exchanged views on future prospects and upcoming trials.

Director's message

Pr Jean BOURHISProf. Jean BOURHISGeneral Director of GORTEC

Dear colleagues, dear friends,

Clinical research is becoming increasingly complex with more constraints for investigators, stricter regulations, and exponentially growing costs for sponsors. In this context, it is essential to preserve and strengthen our academic research potential, particularly through cooperative oncology groups.

Newsletter
GORTEC 2024-04 ILLUMINE : NEWSLETTER N°1 JANUARY 2026
Image is not available

We are pleased to announce that regulatory approvals have been obtained for the activation of the ILLUMINE trial that can now start in France, Belgium, and Spain.

Intergroupe 06_2026
Réunion du GORTEC et de l’IGORL – 18 et 19 juin 2026 – Espaces Vanel de Toulouse
Image is not available

Les inscriptions à la prochaine Réunion du GORTEC et de l'Intergroupe ORL des 18 et 19 juin 2026, qui auront lieu aux Espaces Vanel de Toulouse, ne sont pas encore ouvertes.

Journal
Journal du GORTEC et de l'Intergroupe ORL N°31 - Octobre 2025
Image is not available

Le dernier numéro du Journal du Gortec (n°31 - Octobre 2025) est à présent disponible.

#ASCO25 NivoPostop
#ASCO25
Image is not available

Le Pr Jean Bourhis dévoile en plénière à l’#ASCO2025 les résultats de l’étude NIVOPOSTOP.
Cet essai ,incluant près de 700 patients, avait pour but d'évaluer le bénéfice du nivolumab en post-opératoire dans les cancers ORL.
Résultat phare : une survie sans maladie de 63% à 3 ans, soit +11% de patients guéris grâce à l’immunothérapie.

previous arrowprevious arrow
next arrownext arrow

Gortec's Industrial Partners

	Astra Zeneca
Bicara Therapeutics
Leo Pharma
Merck Group
Merck MSD
Nanobiotix

Trials Newsletters

Last Newsletters available online

Ongoing Clinical Trials

ILLUMINE

Sample image

Newsletter ILLUMINE

ADCC

Sample image

Newsletter ADCC

TPFmORL

Sample image

Newsletter TPFmORL

REWRITe

Sample image

Newsletter REWRITe

NIVOPOST-OP

Sample image

Newsletter NIVOPOST-OP

StereoPostOp

Sample image

Newsletter StereoPostOp

SIMPA01

Sample image

Newsletter SIMPA01

REACH

Sample image

Newsletter REACH

SANTAL

Sample image

Newsletter SANTAL

Pembrorad

Sample image

Newsletter Pembrorad

OMET

Sample image

Newsletter OMET

SALTORL

Sample image

Newsletter SALTORL

Completed, pending publication

Elan

Sample image

Newsletter Elan

Clinical Trials published

TPExtreme

Sample image

Newsletter TPExtreme

Partnership Trials

OSKAR

Sample image

Newsletter OSKAR